Testosteron Mix 400mg/ml 10x1ml Ampullen by Pharma Group

Usage

1. Confirm the batch HPLC report and LAL endotoxin certificate match the ampoule lot number printed on the outer carton before opening any ampoule.
2. Select your weekly dose using the 400mg/ml concentration as the dosing anchor: divide your total weekly milligram target by 400 to calculate the exact millilitre volume required per week.
3. Divide the weekly volume equally across two injection days separated by 72–96 hours (e.g., Monday and Thursday) to exploit the pharmacokinetic overlap between the decanoate tail and the next propionate onset.
4. Score and snap the glass ampoule at the marked break point immediately before drawing; aspirate the full contents using a 19–21 gauge drawing needle, then switch to a 23–25 gauge injection needle for the intramuscular administration.
5. Rotate injection sites across glutes, quads, and delts on a scheduled basis to distribute oil-volume load evenly — the 400mg/ml concentration makes each per-session volume smaller than equivalent 250mg/ml protocols, aiding site recovery.
6. Dispose of each ampoule after a single use; do not store a partially drawn ampoule for a subsequent injection, as the hermetic seal is destroyed on opening.

Warnings

Frequently asked questions

What are the primary benefits of choosing Testosterone Mix 400mg/ml over a standard 250mg/ml four-ester blend?

The primary benefit is volume efficiency: at 400mg/ml, achieving a 400mg weekly dose requires exactly 1ml — one ampoule — versus 1.6ml of a 250mg/ml product. This 37.5% reduction in injected oil per week decreases cumulative injection-site load across a full cycle. The pharmacokinetic profile and ester composition remain identical; only the concentration and therefore the practical administration arithmetic change.

What makes Pharma Group Testosterone Mix 400mg/ml unique compared to other testosterone blends at the same concentration?

Pharma Group's unique position combines the highest available concentration in this product class with single-dose ampoule packaging and dual analytical release documentation. Each batch carries HPLC-confirmed ester-fraction proportions and an LAL endotoxin clearance certificate — both specific to that lot. Most competitors at 400mg/ml offer only aggregate concentration verification rather than fraction-level proportion confirmation.

Why do experienced bodybuilders specifically select a 400mg/ml testosterone ester blend instead of splitting dose across multiple lower-concentration products?

Experienced users favour 400mg/ml blends because the entire weekly dose fits into one or two draws from individual ampoules, simplifying cycle logistics and minimising pin count when running multi-compound protocols. The four-ester architecture also compresses the gap between first androgenic signal and sustained steady-state coverage into a single injection event, whereas achieving that pharmacokinetic range with separate compounds would require at least two distinct esters dosed on separate schedules.

How does the single-dose 1ml ampoule format of this product protect sterility compared to multi-dose vials?

Each glass ampoule is a hermetically sealed, single-use container: it is scored, snapped open, drawn into the syringe, and discarded. There is no rubber septum to puncture repeatedly, no opportunity for airborne contamination between injection events, and no progressive degradation of a preservative buffer. For a 10-ampoule pack across five weeks of twice-weekly dosing, sterile integrity is guaranteed identically for injection one and injection ten.

What practical dosing advantage does 400mg/ml provide for a user targeting 800mg/week in a higher-volume blast phase?

At 400mg/ml, an 800mg weekly dose requires exactly 2ml total — one ampoule per injection on a twice-weekly schedule. The same weekly total from a 250mg/ml formulation would require 3.2ml per week, split as 1.6ml per injection. For athletes already managing bilateral injection rotation with additional compounds, reducing per-session oil volume by 1.2ml per week is a meaningful injection-site comfort and tissue-recovery advantage over a 12-to-16-week cycle. (2) angle_used

Manufacturer

Pharma Group's approach to its multi-ester testosterone portfolio is defined by a specialisation principle that goes beyond simply listing esters on a label: each ester fraction incorporated into the Testosterone Mix 400mg/ml formulation is subject to identity verification against a reference standard at the raw-material intake stage, and fraction-specific proportion confirmation via reversed-phase HPLC at the finished-product stage. This two-point analytical chain — raw API identity at intake, then ester-proportion confirmation at release — is the operational expression of the brand's ester-specialisation mandate within its injectable testosterone segment. The Testosterone Mix 400mg/ml line sits at the apex of Pharma Group's concentration range for multi-ester blends, and the quality architecture applied to it reflects the brand's recognition that higher-concentration products carry proportionally higher documentation obligations: a label claim of 400mg/ml is only meaningful if each of the four constituent ester fractions is analytically confirmed to be present in its intended proportion rather than inferred from aggregate total content alone.